Format

Send to

Choose Destination
Pediatr Blood Cancer. 2011 Aug;57(2):191-8. doi: 10.1002/pbc.23114. Epub 2011 Apr 4.

Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients.

Author information

1
Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada. lee.dupuis@sickkids.ca

Abstract

This guideline provides clinicians caring for children with an approach to assessing the acute emetogenic potential of antineoplastic therapies. It was developed by an international, inter-professional panel of clinicians and researchers using AGREE and CAN-ADAPTE methods. The emetogenicity of antineoplastic agents was evaluated and ranked as high, moderate, low, or minimal. The emetogenicity of multiple-agent and multiple-day antineoplastic therapy was also classified. Gaps in the evidence used to underpin the guideline recommendations were identified. The contribution of this guideline to the prevention of antineoplastic-induced nausea and vomiting in individual children about to receive antineoplastic therapy requires prospective evaluation.

PMID:
21465637
PMCID:
PMC6554029
DOI:
10.1002/pbc.23114
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center